Planning for Prevention of Parkinson's disease: A Trial Design Forum

帕金森病预防规划：试验设计论坛

• 批准号: 10538851
• 负责人: Grace Crotty
• 金额: $ 2.5万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10538851
• 关键词: Advocate; Affect; Biological Markers; Clinical; Clinical Protocols; Clinical Trials; Clinical assessments; Clinical trial protocol document; Communities; Development; Diagnosis; Educational Curriculum; Educational workshop; Elements; Enrollment; Fellowship; Fostering; Funding; Geography; Hybrids; Intervention; Learning; Nerve Degeneration; Neurosciences; Parkinson Disease; Persons; Populations at Risk; Prevention; Prevention Measures; Prevention trial; Research; Research Personnel; Resources; Risk; Testing; Therapeutic; Training; Training and Education; Travel; Update; career; community engagement; design; disorder prevention; exercise intervention; outreach; preventive intervention; programs; symposium; synergism; trial design; virtual

Project summary/ abstract: The proposed conference project will be centered on the “Planning for Parkinson’s Prevention: A trial design forum”, held October 2nd to 3rd, 2022. The overall long-term objectives of this R13 program are to foster the education, training, and future research of investigators in the emerging translational and clinical neuroscience theme of preventative therapeutics for Parkinson’s disease (PD); and to further early initiatives and trial efforts in PD prevention. These project objectives will be achieved through three specific aims (SAs). SA #1 is to provide an update on current research in prevention trial development with a focus on the critical trial design elements (via symposium sessions), and to share and compare emerging clinical trial protocols and initiatives (via presentations and discussion in an interactive session). The symposium portion of the forum will cover i) whom to enroll (genetically and prodromally at-risk populations), ii) what interventions to test, and iii) how to measure prevention of PD or its progression prior to diagnosis (e.g., with biomarker or clinical assessments). SA #2 is to increase research community engagement by enlisting at-risk advocates, providing a hybrid conference format, and publicizing our forum widely. SA #3 is to provide additional training in prevention therapeutics and facilitate networking opportunities for early career investigators through creation of an educational curriculum.

项目总结/摘要： 本次会议的主题是“帕金森病的规划”。 预防：试验设计论坛”，于2022年10月2日至3日举行。整体长远 这个R13计划的目标是促进教育，培训和未来的研究 新兴的转化和临床神经科学主题的研究人员 帕金森病（PD）的预防性治疗;以及进一步的早期举措 和PD预防的试验工作。这些项目目标将通过 三个具体目标（SA）。SA #1是提供当前研究的最新情况， 预防试验开发，重点关注关键试验设计要素（通过 研讨会），并分享和比较新兴的临床试验方案， 倡议（通过互动会议中的介绍和讨论）。座谈会 论坛的一部分将涵盖i）谁入组（遗传和前驱风险 人群），ii）测试哪些干预措施，以及iii）如何衡量PD或PD的预防 其在诊断前的进展（例如，生物标志物或临床评估）。#2是 通过招募处于风险中的倡导者来增加研究界的参与， 混合会议形式，并广泛宣传我们的论坛。#3提供 提供预防治疗方面的更多培训，并为以下人员提供联网机会： 通过创建教育课程，培养早期职业调查员。